The UK's National Health Service (NHS) on Sunday expanded its COVID-19 vaccination programme to cover vulnerable children aged five to 11 years.
Eligible children include those with diabetes, immunosuppression, learning disabilities, and other serious conditions that place them at a high risk from COVID-19.
NHS England said nearly 500,000 eligible children in England are set to receive their first dose of a COVID vaccine in line with advice set out by the Joint Committee on Vaccination and Immunisation (JCVI).
We know vaccines give significant protection against severe illness from COVID including the Omicron variant, so it is important that our youngest and most at-risk get protected, said Dr Nikki Kanani, an Indian-origin GP and deputy lead for NHS vaccination programme.
The NHS is now vaccinating the most at risk 511-year-olds ensuring they get their vital dose of protection. Thousands of young people are still getting protected every day with millions vaccinated so far and we are asking parents not to delay coming forward as soon as the NHS contacts you, please come forward so the NHS can protect their youngest against the virus, she said.
The NHS had earlier opened up vaccines for the over 12 age group and said it has delivered over 3.5 million vaccinations to people aged 12-17, including over 2.4 million first doses.
UK Vaccines Minister Maggie Throup said: I would like parents and guardians to be reassured that no new vaccine for children would have been approved unless the expected standards of safety, quality and effectiveness had been met.
I encourage as many as possible to make sure they get their child the jab when contacted - the paediatric vaccine will offer the best possible protection for your child.
In line with procedures, patient information is sent out to parents and guardians with information on the COVID-19 vaccination. Parents and guardians are asked to attend with their children and are asked to read the patient information in advance of arriving for their appointment.
Eligible children in the youngest cohort will get a second dose eight weeks after their first dose and can't receive any vaccination until four weeks after a positive test for coronavirus.
Last month, the JCVI also issued updated guidance recommending all 16 and 17 year olds get a Pfizer/BioNtech booster from three months (91 days) after their second dose. Following the expansion of a third booster vaccine for all 16 and 17 year olds, over half of eligible young people in this age group have already received their top-up protection.
(Only the headline and picture of this report may have been reworked by the Business Standard staff; the rest of the content is auto-generated from a syndicated feed.)
Dear Reader,
Business Standard has always strived hard to provide up-to-date information and commentary on developments that are of interest to you and have wider political and economic implications for the country and the world. Your encouragement and constant feedback on how to improve our offering have only made our resolve and commitment to these ideals stronger. Even during these difficult times arising out of Covid-19, we continue to remain committed to keeping you informed and updated with credible news, authoritative views and incisive commentary on topical issues of relevance.
We, however, have a request.
As we battle the economic impact of the pandemic, we need your support even more, so that we can continue to offer you more quality content. Our subscription model has seen an encouraging response from many of you, who have subscribed to our online content. More subscription to our online content can only help us achieve the goals of offering you even better and more relevant content. We believe in free, fair and credible journalism. Your support through more subscriptions can help us practise the journalism to which we are committed.
Support quality journalism and subscribe to Business Standard.
Digital Editor
RECOMMENDED FOR YOU